An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib-Reference-Cited by-同舟云学术

An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib

Published:2012-07-30 Issue:6 Volume:158 Page:739-748
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Vij Ravi¹,Siegel David S.²,Jagannath Sundar³,Jakubowiak Andrzej J.⁴,Stewart Alexander Keith⁵,McDonagh Kevin⁶,Bahlis Nizar⁷,Belch Andrew⁸,Kunkel Lori A.⁹,Wear Sandra¹⁰,Wong Alvin F.¹¹,Orlowski Robert Z.¹²,Wang Michael¹²

Affiliation:

1. Washington University School of Medicine; St. Louis; MO; USA

2. John Theurer Cancer Center at Hackensack University; Hackensack; NJ; USA

3. Mount Sinai Medical Center; New York; NY; USA

4. University of Michigan Comprehensive Cancer Center; Ann Arbor; MI; USA

5. Mayo Clinic; Scottsdale; AZ; USA

6. University of Kentucky College of Medicine; Lexington; KY; USA

7. Tom Baker Cancer Centre; University of Calgary; Calgary; AB; Canada; AB; USA

8. University of Alberta Cross Cancer Institute; Edmonton; AB; Canada

9. Independent Consultant; San Francisco; CA; USA

10. Multiple Myeloma Research Consortium; Norwalk; CT; USA

11. Onyx Pharmaceuticals, Inc; South San Francisco; CA; USA

12. MD Anderson Cancer Center; Houston; TX; USA

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2012.09232.x/fullpdf

Reference37 articles.

1. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies;Alsina;Blood (ASH Annual Meeting Abstracts),2007

2. Nonproteasomal targets of the proteasome inhibitors bortezomib and carfilzomib: a link to clinical adverse events;Arastu-Kapur;Clinical Cancer Research,2011

3. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation;Blade;British Journal of Haematology,1998

4. Follow-up psychophysical studies in bortezomib-related chemoneuropathy patients;Boyette-Davis;Journal of Pain,2011

Cited by 156 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their Introduction;International Journal of Molecular Sciences;2024-08-16

2. Empagliflozin Alleviates Carfilzomib-Induced Cardiotoxicity in Mice by Modulating Oxidative Stress, Inflammatory Response, Endoplasmic Reticulum Stress, and Autophagy;Antioxidants;2024-05-30

3. Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study;JMIR Research Protocols;2024-04-24

4. Real-World Registry on the Pharmacotherapy of Multiple Myeloma and Associated Renal and Pulmonary Impairments in the Greater Gulf Region: Protocol for a Retrospective Real-World Data Study (Preprint);2023-06-12

5. Preclinical Overview of Drugs Affecting Protein Turnover in Multiple Myeloma;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15